ERIS1,358.00

Eris Lifesciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹18,808 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,009.12,893.63,129.43,229.7
Other Income23.818.47.87.5
Total Income2,033.02,912.03,137.23,237.1
Expenses
+ Cost of Materials Consumed177.8276.3326.7350.8
+ Purchases of Stock-in-Trade201.5473.1490.6517.4
+ Changes in Inventories0.7-35.5-21.6-18.0
+ Employee Benefit Expense403.8505.1556.8565.8
+ Finance Costs84.8231.3192.7190.6
+ Depreciation & Amortisation182.6315.5279.5281.1
+ Other Expenses550.5657.4656.9674.1
Total Expenses1,601.72,423.22,481.52,561.8
EBITDA674.81,017.21,120.11,139.6
EBIT492.2701.7840.6858.6
Profit
PBT before Exceptional Items431.2488.8655.7675.4
+ Exceptional Items0.00.0-17.2-17.2
Pretax Income431.2488.8638.5658.1
+ Current Tax82.2111.8157.4132.2
+ Deferred Tax-48.02.4-166.4-141.0
Tax Expense34.2114.2-9.0-8.8
+ Share of Associates & JVs0.00.10.1-1.2
Net Income397.1374.7647.5665.7
+ Net Income — Continuing Ops397.1374.6647.4666.9
+ Other Comprehensive Income-3.1-3.3-1.4-0.8
Total Comprehensive Income394.0371.4646.1664.9
Net Income to Common392.0351.8619.5644.0
Minority Interest5.122.828.021.8
Per Share
Basic EPS28.8225.8545.3347.02
Diluted EPS28.7925.8145.2646.95
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs0.00.0-0.1
Other Comprehensive Income — detail
+ Other Comprehensive Income-3.3-1.4-0.8
+ Items NOT to be Reclassified to P&L-4.6-3.60.1
+ Tax on Items NOT to be Reclassified-0.3-0.21.2
+ Tax on Items NOT to be Reclassified — alt tag-1.6
+ Items to be Reclassified to P&L-2.4
+ Tax on Items to be Reclassified-0.6-0.9
Comprehensive Income — Owners of Parent388.9348.7618.1500.7
Comprehensive Income — Non-controlling Interests5.122.728.020.9
Per Share — as-filed variants
Basic EPS — Continuing Operations28.8225.8545.3347.02
Diluted EPS — Continuing Operations28.7925.8145.2646.95
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,629.12,179.72,333.82,379.5
Gross Margin %81.0875.3374.5873.68
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)431.2488.8655.7675.4
− Exceptional Items (reconciliation)0.00.0-17.2-17.2
Net Income Adj (tax-effected)397.1374.7664.8683.0
EPS Adj28.8225.8546.5448.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Filed Debt Equity0.010.010.01
Filed Dscr0.020.030.03
Filed Iscr0.030.040.05
Paid Up Equity Capital13.613.613.913.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.